Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110133 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
A Phase 2 study of Clostridium Difficile Infection Recurrence, sponsored by Finch Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT03110133: Completed Phase 2 study of Clostridium Difficile Infection Recurrence, sponsored by Finch Research and Development.
NCT03110133 is a Phase 2 study of Clostridium Difficile Infection Recurrence that has completed, run by Finch Research and Development. The registered enrollment target is 206 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03110133, a Phase 2 study of Clostridium Difficile Infection Recurrence, has completed, sponsored by Finch Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II. The purpose of this study is to demonstrate the safety and effectiveness of CP101 to prevent recurrence of C. difficile. Subjects with confirmed C. difficile recurrence within 8 weeks after administration of study drug (CP101 or placebo) may be eligible to enroll in the open-label extension study (CP101-CDI-E02) and will receive CP101.
Primary Outcome
Defined in the protocol as sustained clinical cure
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Full Spectrum Microbiota
Study Locations (20)
California
- Los Angeles - Los Angeles
- Murrieta - Murrieta
- Oakland - Oakland
- San Diego - San Diego
- San Francisco - San Francisco
Florida
- Jacksonville - Jacksonville
- Naples - Naples
- Pinellas Park - Pinellas Park
- Tampa - Tampa
Illinois
- Burr Ridge - Burr Ridge
- Chicago - Chicago
- Evanston - Evanston
- Maywood - Maywood
Connecticut
- Bridgeport - Bridgeport
- Hamden - Hamden
Arizona
- Scottsdale - Scottsdale
Colorado
- Aurora - Aurora
District of Columbia
- Washington DC - Washington D.C.
Georgia
- Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2020-06-18 |
| Phase | Phase 2 |
What the finished NCT03110133 record still lists
NCT03110133 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Clostridium Difficile Infection Recurrence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03110133 names 20 study sites across 9 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03110133 about?
NCT03110133 is a clinical study titled "Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff". Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II. The purpose of this study is to demonstrate the safety and effectiveness of CP101 to prevent recurrence of C. difficile. Subje...
What is the current status of trial NCT03110133?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2017-05-08. Estimated completion is 2020-06-18.
What conditions does trial NCT03110133 study?
This clinical trial studies the following conditions: Clostridium Difficile Infection Recurrence.
What interventions are being tested in trial NCT03110133?
The interventions under investigation include: Placebo (DRUG), Full Spectrum Microbiota (DRUG).
Who is sponsoring clinical trial NCT03110133?
This trial is sponsored by Finch Research and Development, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03110133 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Infection Recurrence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03110133's enrollment target sits among peer trials
206 298th of 2000 higher than 1,703 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI